Advancing the Future of Oncology
Advancing therapies with
hidden cancer targets
In immunotherapy, success begins with the right target. Traditional antibody therapies often fail because cancer cell surface proteins are also found on healthy cells- leading to on-target, off-tumor effects and limited efficacy.
Eximmium is redefining cancer therapy by uncovering novel, tumor-specific targets and pairing them with first-in-class monoclonal antibodies. Our proprietary platform technology has yielded a growing portfolio of antibodies and related products against previously undruggable proteins.
We focus on intracellular proteins that are abnormally presented on the surface of cancer cells—highly specific and accessible targets for antibodies and cell therapies like CAR-T.
Our focus:
01.
Novel intracellular targets
02.
Early clinical translation
03.
Pioneering innovation
Unlocking intracellular targets:
The EximAB™
Platform
Conventional immunotherapies risk off-tumor toxicity by targeting non-specific proteins. Traditional antibody discovery also struggles with non-native antigens. Our proprietary platform technology overcomes both limitations.
Vesicles for target discovery
Extracellular vesicles (EVs) from cancer cells reflect their surface proteome, providing a rich source of novel, tumor-specific targets — a core element leveraged by our EximAB™ platform.
EximAB™ Platform
With EximAB™, we identify intracellular proteins abnormally exposed on cancer cell surfaces and generate novel antibodies that bind native membrane conformations, thus enhancing clinical relevance.
First-in-class antibodies
By discovering novel, truly cancer-specific targets and generating high-affinity antibodies simultaneously, we create safer and more precise immunotherapies.
From discovery to Phase I
At Eximmium, we combine scientific innovation with clinical expertise to translate breakthrough discoveries into first-in-human trials.
Therapeutic
Pipeline
Target
Indication
Format
mAb
Non-clinical
CMC manufact.
IIT
Phase I
SRRM2
Multiple Myeloma
CAR-T
SRRM2
Pancreatic cancer
CAR-T
SRRM2
Pancreatic cancer
ADC
SRRM2
SCLC
ADC
SRRM2
Oncology
BiTe
EX01
Oncology
mult.
n.d.
Oncology
mult.
SRRM2 -
a new target on tumor cells
From immunizations with extracellular vesicles from cancer cell lines, we obtained antibodies targeting SRRM2, a RNA-binding protein involved in splicing and a major component of nuclear speckles.
We were the first to demonstrate, that SRRM2 is exposed on the surface of many different cancer cell lines and on patient-derived cancer cells. We currently investigate the functionality of SRRM2-specific CAR T cells in preclinical models and first-in-man studies.
Panel A: Confocal microscopy revealed that our antibodies preferentially bind to surface SRRM2, whereas commercially available antibodies only target the intracellular protein. Panel B: immuno-histochemistry with our SRRM2 antibody of a serous ovarian carcinoma (left) and adjacent normal tissues (right) shows specific surface staining of cancer cells.
latest
Publications
Get an insight into our scientific work.
The nuclear speckles protein SRRM2 is exposed on the surface of cancer cells (2024)
SARS-CoV-2 and Epstein–Barr virus-like particles associate and fuse with extracellular vesicles in virus neutralization tests (2023)
Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test (2022)
Poster: A new class of universal reference EVs
Let´s get in touch
Interested in working with us or learning more about our antibodies and targets? We are looking forward to hearing from you.
